Skip to content

Over 50s do just as well on HIV treatment, but more likely to be diagnosed late and to change treatment sooner

IAS: Pendulum swinging towards early treatment as burden of pre-AIDS illness recognised

IAS: Truvada more effective than Kivexa due to drop-outs related to abacavir hypersensitivity

IAS: Screening for B*5701 reduces abacavir hypersensitivity incidence to zero

IAS: Regular dietician consultation effective at preventing HAART-associated dyslipidaemia

IAS: Maraviroc slightly less effective but more tolerable in treatment-naive patients

IAS: Integrase inhibitor raltegravir (MK-0518) potent, durable and more tolerable than efavirenz in treatment-naive at 48 weeks

Booster therapy after starting HIV treatment may offer way of reducing long-term drug burden

Risk of viral rebound decreases with longer treatment, even with previous failures